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Purpose: To identify novel mutation in the PAX6 (paired box gene 6) gene and characterize new clinical features of severe
ocular malformation in a Chinese patient with Peters’ anomaly.
Methods: A 10-month-old male infant, who presented with corneal opacity and nystagmus, was referred to our pediatric
clinic and underwent a complete general physical and ophthalmological examination, including anterior segment and
retinal evaluation with slit-lamp microscopy, an A/B ultrasonic scan, and electroretinography (ERG). Genomic DNA was
prepared from venous leukocytes. The coding regions and the adjacent intronic sequence of PAX6 were amplified by a
polymerase chain reaction, and subsequently analyzed by direct sequencing. The variation detected was further evaluated
in 100 controls using heteroduplex- single strand conformational polymorphism (SSCP) analysis.
Results: The patient had bilateral Peters’ anomaly showing congenital nystagmus, corneal leukoma with anterior synechia,
anterior polar cataract, and his pupils could not be dilated because of posterior synechia. Electroretinography (ERG)
demonstrated retina hypogenesis and an A/B ultrasonic scan showed microphthalmus. A novel mutation: C.51C>A (P.
N17K) was identified in PAX6 while this mutation was absent in 100 normal controls. This mutation, which affects highly
conserved amino acid, has not been previously reported.
Conclusions: PAX6 mutations cause ocular malformations that vary considerably in pattern and severity. In this study,
we identified one novel mutation in PAX6 in a patient with severe ocular clinical features of Peters’ anomaly. This finding
expands the mutation spectrum in PAX6 and enriches our knowledge of genotype-phenotype relations due to PAX6
mutations.
The PAX6 gene (OMIM 607108, paired box gene 6, a
paired box transcriptional factor) is located on chromosome
11p13, consists of 14 exons, and encodes 422 amino acids
[1,2]  as  a  transcriptional  regulator  (expressed  in  the
developing central nervous system and various ocular tissues),
and is involved in eye morphogenesis. PAX6 is a key regulator
of  eye  development,  and  there  are  many  well  recognized
ophthalmic sequelae of mutations at this locus. Human PAX6
mutations have been associated with a variety of congenital
eye  malformations.  Mutations  in  PAX6  result  mainly  in
aniridia [3,4]. Also, in rare cases, PAX6 mutations cause other
ocular abnormalities such as congenital cataracts [5], Peters’
anomaly [6,7], corneal dystrophy [8], autosomal dominant
keratitis,  foveal  hypoplasia,  microphthalmia,  optic  nerve
malformations  including  coloboma,  morning  glory  disc
anomaly, and optic nerve hypoplasia [9,10].
Peters’ anomaly is congenital and affects the anterior
segment of the eye. This disease is most often sporadic but
may be recessive or occasionally dominant in inheritance. The
Peters’  phenotype  varies  greatly.  The  essential  feature  of
Peters’ anomaly is a congenital central corneal opacity. The
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size and density of the opacity can range from a faint stromal
opacity to a dense opaque central leukoma. The phenotypes
may  be  isolated  or  accompanied  by  other  ocular
malformations.  Other,  less  frequent,  ocular  abnormalities
occur  in  the  microcornea,  microphthalmos,  cornea  plana,
sclerocornea, colobomata, dysgenesis of the angle and iris,
ptosis, optic nerve, and foveal hypoplasia [11-13].
The mutations in PAX6 in patients with Peters’ anomaly
have been rarely reported, especially among Chinese patients.
In this study, PAX6 mutation analysis and detailed clinical
evaluation were performed to identify novel mutation and
characterize new clinical features of severe Peters’ anomaly
ocular malformation in a Chinese patient.
METHODS
Patients  and  clinical  data:  A  10-month-old  male  infant
presenting with corneal opacity and nystagmus was referred
to our Pediatric and Genetic Clinic in the Eye Hospital of the
Zhongshan Ophthalmic Center, Guangzhou, China. Written
informed consent was obtained, the study was approved by
the Ethics Committee of the Zhongshan Ophthalmic Center,
and was performed according to the tenets of the Declaration
of Helsinki. Medical and ophthalmic histories were obtained.
A  complete  general  physical  examination  and  a  detailed
ophthalmological  examination,  including  anterior  segment
observation  with  slit-lamp  microscopy  and  intraocular
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676Figure 1. Novel PAX6 mutation identified in exon 5 of the patient.
A heterozygous mutation in PAX6 was exclusively detected in the
affected patient and the mutation was confirmed by bidirectional
sequencing,  which  the  underline  indicates.  The  other  underline
shows  the  corresponding  normal  sequence  from  the  unaffected
control individual.
Figure 2. The bipartite paired DNA-binding domain of PAX6. The
yellow segment represents the mutation region.
TABLE 1. OLIGONUCLEOTIDES USED FOR PAX6 AMPLIFICATION.
Exon Sequences (5′-3′) Annealing temperature (°C)
4 F:TGATGCAGCTGCCCGAGGATTA 68
  R:GGGGCGAGAGGGGGTGTGAGTTA  
5 F:TTCCCCTTCCTCCTCTCCTTTCT 62.4
  R:GGGGGTCCATAATTAGCATCGTT  
6 F:GCAAGGTCAGCACAAAAATAAAT 66.5
  R:TGCCCTGGGTCTGATGGA  
7 F:AAAACGTAAGCTTGTCATTGT 58
  R:GAGAGGGTGGGAGGAGGTA  
8 F:TTCCATGCCCAAAGTGATAG 60
  R:TTCCCAGGCCAACAAAAT  
9 F:AAAATGGTGGTCAGGTAACTAAC 62.4
  R:TGAAAAGATGCCCAGAGAAATAA  
10 F:TTGGTTGGAGGTAATGGGAGTG 62.4
  R:GGAAATCAGGTGGGACAGGTTAG  
11 F:CGTGGGGAGGGCAGCAGTG 68
  R:ATGGAGCCAGATGTGAAGGAGGAA  
12 F:GAAGGGCCAAATGGAGAAGAGA 68
  R:TGCAGACACAGCCAATGAGGT  
13 F:GACTAGCTCGAGGCCCAATCTTA 64.8
  R:TTCCCTTTTCAATCCCCATCC  
14 F:TTGCTGGAAATAAAAAGTGA 58.9
  R:CGGCTCTAACAGCCATTTTT  
H-SSCP analysis of exon 5. F:TTCTCCCTCATCTTCCTCTTCCTT 64.8
  R:GCAGTGGCCGCCCGTTGAC  
A sequence of oligonucleotides and annealing temperatures was used for exon-by-exon PAX6   amplification. In the table, “F”
indicates the forward strand and “R” indicates the reverse strand. Sequences are given in the 5′-3′ direction.
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677pressure (IOP) measurement, were performed by Drs. Zhang
and  Guo.  An  A/B  ultrasonic  scan  and  ERG  was  used  to
evaluate the ocular and retinal hypogenesis of dysmorphic and
functional findings.
Mutation  screening:  Genomic  DNA  was  prepared  from
venous blood. All of the primers for PAX6 (Table 1) were used
to amplify coding exons (exon 4 to exon 14 of PAX6) and the
adjacent intronic sequence of the two genes (NCBI human
genome build 35.1, NC_000011.8 for gDNA, NM_001604.3
for cDNA, and NP_001595.2 for protein of PAX6). The PCR
products of the exons and adjacent intronic sequences for the
patient were sequenced with the ABI BigDye Terminator
cycle sequencing kit v3.1 (ABI Applied Biosystems, Foster
City, CA) according to the manufacturer’s recommendations,
using a 3100 sequencer confirmed by ourselves. Sequencing
results from patients, as well as consensus sequences of PAX6
from  the  NCBI  human  genome  database  (NM_001604.3)
were imported into the SeqManII program of the Lasergene
package (DNAStar Inc., Madison, WI) and aligned to identify
variations.  Each  mutation  was  confirmed  by  bidirectional
sequencing.  Mutation  was  named  according  to  the
nomenclature  recommended  by  the  Human  Genomic
Variation Society (HGVS).
Heteroduplex-SSCP analysis: The variation detected in the
gene was further evaluated in 100 normal controls (informed
consent, in accordance with the Declaration of Helsinki, was
obtained from the participating individuals before the study)
by using heteroduplex-SSCP analysis as previously described
in the literature [14-16]. DNA fragments of 152 bp-spanning
mutation sites were PCR-amplified according to Table 1. PCR
product was mixed with an equal volume of gel-loading buffer
(95% formamide, 20 mM EDTA, and 0.05% bromophenol
blue, 0.05% xylene cyanol), and denatured at 95 °C for 5 min
and immediately placed on ice for 5 min. The samples were
loaded directly onto 8% polyacrylamide gels and run 8 h at
room temperature at 40 w in a solution of 0.5× TBE.
RESULTS
A novel heterozygous mutation, c.51C>A in PAX6 (Figure 1),
was identified. The nucleotide substitution of PAX6 would
result  in  replacement  of  Asparagine  by  lysine  (i.e.,
P.Asn17Lys) at codon17. The mutation (Figure 2) is in a
bipartite-paired  DNA-binding  domain.  The  p.  Asn17Lys
mutation identified in this study changed from an amide-type
amino acid to a basic amino acid, which results in a change at
the protein level with a residue weight from six to zero on
Blosum  62,  as  well  as  a  “probable  damaging”  effect  by
PolyPhen.  Asparagine  in  this  position  was  found  highly
conserved for PAX6 by analyzing 7 orthologs from different
vertebrate species (Figure 3). This missense mutation was also
analyzed in 100 unaffected control individuals (Figure 4) by
heteroduplex-SSCP, but none was identified.
The patient with this mutation of PAX6 was a 10-month-
old boy, born at full term after a normal delivery. His parents
were not consanguineous and were healthy. Corneal opacity
and nystagmus were present in both eyes of the patient at birth.
Examination  under  anesthesia  showed  that  his  corneal
diameter was small–horizontal 9.5 mm and vertical 9 mm–for
both eyes, and A-scanning demonstrated microphthalmia with
Figure 4. The mutation was detected by heteroduplex-SSCP analysis.
Abnormal  migrational  SSCP  band  patterns  in  the  mutation  are
demonstrated as compared with normal. Line 1, sample from the
affected  individual;  lines  2  through  6,  Samples  from  unaffected
control  individuals  (NC).  The  arrow  indicates  the  band  that  is
different from the NC samples.
Figure  3.  The  mutation  involved  a
highly conserved residue. As shown in
the square, the threonine at position 17
is highly conserved for PAX6, which
was  demonstrated  by  analysis  of  7
orthologs  from  different  vertebrate
species.
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678an axial length of 18.06 mm in the right eye and 18.07 mm in
the left eye. Schiotz Tonometry showed that IOP was normal.
The corneal opacity in the deep corneal stroma was irregular
and fibrous adhesions between the corneal endothelial surface
and  the  iris  existed  in  both  eyes.  The  anterior  chamber
appeared extremely shallow under microscopic examination.
His iris texture was not clear, presenting in screen stencil, and
the pupils could not be dilated using 0.5% tropicamide. The
patient also had an anterior polar cataract with the central lens
uplifted slightly. The former pole was turbid (Figure 5). The
fundus could not be seen clearly by RetCom II because of the
corneal  opacity  and  the  cataract.  ERG  examination
demonstrated retinal dysphasia. A dramatic reduction of cone-
specific ERG amplitude, with a more striking reduction in rod
b-wave amplitude, was observed. We found no recordable
rod-specific  response  to  the  ERG  stimuli,  while  lower
amplitude but normal latency of cone cells, delayed latency,
and  reduced  amplitude  of  mixed  response  were  observed
(Figure 6). B-scanning showed that vitreous was opaque and
an acoustic image of the binocular optic nerve showed that it
was not smooth (Figure 7). A systemic examination showed
that  the  respiratory,  cardiovascular,  and  central  nervous
systems were normal in this patient.
DISCUSSION
Genetic analysis has detected numerous mutations in PAX6 in
sporadic cases or in families. Most previous mutations of
PAX6 have been associated with aniridia. In this study, a novel
mutation (c.51C>A) in PAX6 was identified in a Chinese
patient.  The  signs  of  the  patient  suggest  a  group  of
developmental abnormalities in his eyes from the anterior
segment  to  the  posterior  segment,  which  has  been  rarely
reported. All of the clinical signs and examinations show that
the  boy  has  serious  ocular  eccyliosis  of  Peters’  anomaly
[11-13].
Figure 5. Ocular manifestations in the proband. The pictures show the aspects of the ocular anterior segment as well as of the lens of the
patient. The proband had microcornea, microphthalmia, congenital corneal leukoma, iris dysplasia, and anterior polar cataracts in both eyes. In
A (right eye) and B (left eye), arrowheads point to adherent corneal leucoma and arrows point to anterior polar cataracts.
Figure  6.  ERG  examination  of  the
patient.  The  results  showed  that  the
responses of the rod cells and cone cells
were abnormal.
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679The  ERG  measurements,  which  presented  acute  rod
damage and attenuating function of surviving cones, reveal
abnormalities in the visual cycle of the rods and cones, which
may  suffer  comparable  photoreceptor  dystrophies.  We
focused on the development of photoreceptors to gain a better
understanding of the molecular and cellular mechanisms that
cause abnormal ERG. PAX6 and CRX (cone-rod homeobox
containing  gene)  are  essential  during  early  retinal
development  and  for  photoreceptor  differentiation.  PAX6
expresses  during  the  early  steps  of  photoreceptor
development, and acts as an activator of proneural genes in
terms  of  the  promotion  of  progenitor  proliferation,
maintenance  of  progenitor  potential,  and  cell  fate
specification. To our knowledge, PAX6 protein can bind to the
CRX  promoter  region  in  a  selective  manner  [17],  which
supports  its  role  as  a  direct  transcriptional  repressor  of
photoreceptor fate. However, CRX is a photoreceptor-specific
transcription  factor  that  plays  a  crucial  role  in  the
differentiation of photoreceptors, and mutations in the human
homolog CRX, causes cone–rod dystrophy [18]. This may be
a mechanism by which the specific PAX6 mutation in our
study leads to abnormal ERG. This missense mutation that
produced developmental disorders of the patient in our study
can be explained by the PAX6 protein structure. Many studies
Figure 7. Ocular manifestations of B-scanning. B-scanning revealed
the abnormal structure of the vitreous body and optic nerve.
have determined the crystal structure of the human PAX6
paired domain with its optimal DNA-binding site [1,2,4].
The  N  subdomain  of  PAX6  uses  a  helix–turn–helix
(HTH) unit to dock against the major groove at one end of the
binding site [19]. The crystal structure reveals specific DNA
contacts made by the N subdomain, which plays a dominant
role in DNA binding of the intact paired domain, and provides
a general model for understanding PAX6 mutations and the
protein–protein  and  protein–DNA  interactions  that  are
relevant for the biologic function of the paired domains. The
mutation may affect the HTH structure and result in changes
in structure and function. To our knowledge, the mutation in
the  study  alters  the  nucleotide  sequence  within  the  N
subdomain just at its optimal DNA-binding site. In PAX6,
Asn-17 can directly contact DNA. The side chain of Asn-17
that lies at the DNA–protein interface in the β turn region
(residues  16–19)  makes  a  hydrogen  bond  with  the  N  of
guanine 9 and makes a water-mediated hydrogen bond with
the same guanine [19]. In theory, the p.Asn17Lys mutation
would be expected to influence the function of PAX6 protein
if it is expressed. Mutation would be predicted to result in
proteins with dominant negative functions or novel functions,
which could have profound effects on the development of the
tissues where PAX6 is normally expressed.
In terms of correlations between phenotype and mutation
type, many researchers pointed out that aniridia phenotypes
were  caused  by  mutations  that  introduce  a  premature
termination  codon  (PTC),  while  non-aniridia  phenotypes
were caused by missense mutations. They also suggested that
3′ mutations, which introduce a PTC into the PAX6 open
reading frame, do in fact yield dominant negative alleles that
may cause more severe phenotypes than missense mutations
[20,21]. However, in our report the missense mutation in the
N subdomain can also produce serious phenotypes of Peters’
anomaly.
The potential disease-causing mutation in PAX6 of the
index cases is not very prevalent; this may be accidental due
to the relatively small number of sporadic patients. It seems
likely that additional genes with yet unknown functions in
anterior segment development may contribute to the spectrum
of Peters’ anomaly.
These results expand the mutation spectrum in PAX6 and
enrich our knowledge of genotype-phenotype relations due to
the mutation. Correlating phenotype to the site of the missense
mutation should be further studied. As more mutations are
analyzed, it may become possible to correlate the position of
a mutant, and the relative effect of the mutation on DNA
structure, with the observed developmental defects.
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